FXVIEW Goes Global, Sets up a Subsidiary in Saint Vincent and Grenadines
21.6.2021 10:47:00 EEST | Business Wire | Press release
Fxview, Cyprus based forex and CFDs financial services company, announced today that it has set up an offshore subsidiary in St Vincent & The Grenadines. Until now, Fxview has been operating with its EU licenses from Cyprus.
Charlgate SVG LLC, their locally incorporated arm will ensure the expansion of products and services on Fxview’s platforms. It will also allow them to offer regulated forex and CFDs trading services to traders around the globe.
Fxview operates in Europe with its multiple European Licenses and is already an established brand in the EU market. Earlier this month, the company was acquired by a global FinTech leader Finvasia Group.
“We anticipate that many more traders will join our platform where we plan to offer additional products and services like research & analysis, higher leverage, sophisticated trading tools, social trading, MAM / PAMM services, affiliate programs, loyalty reward programs and more,” said Rahul Bansal, Director of Charlgate SVG LLC.
“We have been successfully operating uninterrupted in the trading industry for more than a decade, and one of our missions has always been to grow our regulatory framework,” said Sarvjeet Virk, Managing Director of FINVASIA Group.
“The offshore entity is a key milestone for Fxivew. This will allow our existing and new clients to take full advantage of our innovative ecosystem ranging from state-of-the-art platforms & tools, lightning-fast execution, excellent trading conditions and stellar customer support” he further added.
About Fxview
Fxview is a brand owned and operated by Charlgate Ltd (a Finvasia Group Company) with its headquarters in Limassol Cyprus. Charlgate Ltd operates under the European Markets in Financial Instruments Directive (MiFid) and is regulated by CySec under license 367/18 since 2018 and is a Member of the Investor Compensation Fund (ICF).
Charlgate Ltd is also registered with the UK Financial Conduct Authority – FCA ( 850138), the German Federal Financial Supervisory Authority – BaFin ( 157125), the French Autorité de Contrôle Prudentiel et de Résolution – ACPR ( 85051), the Italian Commissione Nazionale per le Società e la Borsa – CONSOB ( 5151), the Spanish Comisión Nacional de Mercado de Valores – CNVM ( 4892), the Norway Finanstilsynet – ( FT00118545).
Know more: https://fxview.com/
About FINVASIA Group
FINVASIA is a multi-disciplinary, multinational organisation that invests in technology-oriented business and products. It is registered with a gamut of regulatory bodies across the world in various capacities. Finvasia (along with its subsidiaries and sister concerns) is registered with SEC, USA (152771 ), Reserve Bank of India as an NBFC, National Stock Exchange of India as Professional Clearing member(M51912), Bombay Stock Exchange(4043), Multi Commodity Exchange of India(55135) and NCDEX as Trading Member(01259), Association of Mutual Funds of India(103331) and CDSL as Depository Participant(12084300).
Know more: https://finvasia.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005285/en/
Contact information
Media:
Ms. Sandeep Samra
media@fxview.com
+35725251100
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom